Drug Type Monoclonal antibody |
Synonyms CLM-101, NOV 1105, YYB 101 + [1] |
Target |
Action inhibitors |
Mechanism HGF inhibitors(Hepatocyte growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal cancer recurrent | Phase 2 | United States | 09 Aug 2019 | |
Colorectal cancer recurrent | Phase 2 | United States | 09 Aug 2019 | |
Metastatic Colorectal Carcinoma | Phase 2 | United States | 09 Aug 2019 | |
Metastatic Colorectal Carcinoma | Phase 2 | United States | 09 Aug 2019 | |
Colorectal Cancer | Phase 2 | South Korea | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 13 Jul 2015 | |
Ovarian Cancer | Preclinical | South Korea | 04 Jul 2023 | |
Pancreatic Cancer | Preclinical | South Korea | 04 Jul 2023 |
Phase 1/2 | Colorectal Cancer Last line | 35 | YYB101+ irinotecan | rxqwkgclhs(puenffqoje) = zsmwrimpyu snutcfpxfd (qwrtltzrjp ) View more | Positive | 22 Oct 2023 | |
Phase 1 | 39 | iuchjpxvzg(nxmcmabtzj) = zqagjwugtg dvrspfosab (nxfpmyzowk ) View more | Positive | 02 Jun 2020 | |||
Phase 1 | 39 | qyjzimcvxo(djtdrmykfz) = nmvvkadelq dfsbkbyrlz (xjcwjwefbt ) View more | Positive | 26 May 2019 | |||
Phase 1 | 22 | sejajrufoa(lckvwotdix) = anorexia, ALT increase, azotemia were observed at later dose aascygnigt (umcwuprqmv ) | Positive | 01 Jun 2018 |